The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
WuXi Biologics, a global CRDMO, has launched TrueSite TI, a targeted integration (TI)-based CHO cell line platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback